Lithocholic acid inhibits dendritic cell activation by reducing intracellular glutathione via TGR5 signaling

作者：Jianping Hu, Yiting Zhang, Shenglan Yi, Chaokui Wang, Xinyue Huang, Su Pan, Jinglu Yang, Gangxiang Yuan, Sisi Tan, Hong Li · 发表于：International Journal of Biological Sciences · 年份：2022 · DOI：10.7150/ijbs.71287 · 被引用次数：51 · 研究领域：Drug Transport and Resistance Mechanisms、Reproductive System and Pregnancy、Pregnancy and Medication Impact

Dendritic cells (DCs) are the major antigen-presenting cells and play an important role in autoimmune uveitis. Emerging evidence suggests that bile acids (BAs) regulate DCs maturation. However, the underlying mechanisms by which BAs regulate the function of DCs still need to be clarified. Here, we demonstrate that lithocholic acid (LCA) inhibits the production of pro-inflammatory cytokines and the expression of surface molecules in bone marrow-derived dendritic cells (BMDCs). LCA attenuates the severity of EAU by modulating the maturation of splenic CD11C + MHCII high DCs. Notably, Takeda G-protein coupled receptor 5 (TGR5) deficiency partially reverses the inhibitory effect of LCA on DCs in vitro and in vivo. TGR5 activation also downregulates the NF-B and MAPK pathways by inhibiting glutathione production and inducing oxidative stress in DCs, which leads to apoptosis and autophagy in DCs. In addition, LCA or INT-777 treatment increases the TGR5 expression in monocyte-derived dendritic cells (MD-DCs) of patients with active BD, whereas both LCA and TGR5 agonists inhibit the activation of MD-DCs. These results suggest that LCA and TGR5 agonists might be potential therapeutic drugs for the treatment of autoimmune uveitis.